🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

150 results for “chemotherapy” Clear

  1. 2 cycles induction chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  2. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  3. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  4. APF530

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  5. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  6. Adjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Total Neoadjuvant Treatment

    phase 3 small molecule active

    1 trial

  7. Balugrastim

    Teva Pharma GmbH

    Chemotherapy-induced Neutropenia

    phase 3 mab completed

    1 trial

  8. Capox chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  9. Chemotherapy

    The First People's Hospital of Lianyungang

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  10. Chemotherapy

    International Peace Maternity and Child Health Hospital

    Non Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  11. Chemotherapy

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  12. Chemotherapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  13. Chemotherapy

    United Therapeutics Europe Ltd

    Transitional Cell Carcinoma of Ureter

    phase 3 small molecule active

    1 trial

  14. Chemotherapy + avelumab followed by avelumab + talazoparib

    Pfizer

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  15. Chemotherapy drug

    Chinese PLA General Hospital

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  16. Concurrent chemotherapy

    Disc Medicine

    Uterine Cervical Neoplasms

    phase 3 small molecule active

    1 trial

  17. Durvalumab + SoC chemotherapy

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  18. ELECTROLYTES , VIALEBEX 200 g/L, solution pour perfusion

    Pari Pharma GmbH

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

    phase 3 small molecule active

    1 trial

  19. ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  20. HIPEC with neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  21. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 3 other active

    1 trial

  22. IVEMEND 150 mg powder for solution for infusion, Aprepitant Placebo Tablet, Aprepitant Teva 80 mg, harde capsules, NaCl I.V.

    AXIM BIOTECHNOLOGIES, INC.

    Delayed chemotherapy induced nausea and vomiting (CINV)

    phase 3 small molecule active

    1 trial

  23. IVEMEND 150 mg powder for solution for infusion, fosnetupitant chloride 260 mg/palonosetron 1.5 mg, fosnetupitant chloride 260 mg/palonosetron 2.5 mg, Ondansetrone Hikma 8 mg/4 ml Soluzione iniettabile, Sodium Chloride Injection BP 0.9% w/v

    Helsinn Birex Pharmaceuticals Ltd

    Chemotherapy-induced nausea and vomiting

    phase 3 small molecule active

    1 trial

  24. Induction Chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources